Table I.
Clinical characteristics of patients treated with the VTD regimen.
| Parameter | Value |
|---|---|
| Sex, n (%) | |
| Female | 97 (47.3) |
| Male | 108 (52.7) |
| ISS stagea, n (%) | |
| 1 | 71 (34.6) |
| 2 | 45 (22.4) |
| 3 | 88 (43.0) |
| R-ISS stageb, n (%) | |
| 1 | 22 (24.4) |
| 2 | 47 (52.2) |
| 3 | 20 (22.2) |
| Protein M type, n (%) | |
| IgG | 118 (57.6) |
| IgA | 41 (20.0) |
| Light chain MM | 39 (19.0) |
| IgM | 3 (1.45) |
| Monoclonal light chain, n (%) | |
| Kappa | 113 (55.1) |
| Lambda | 88 (42.9) |
| Non-secretory | 4 (1.95) |
| Albumin, g/l, median; (min-max) | 3.6; (1.8–5.2) |
| β-2-microglobulin, mg/l, median; (min-max) | 4.1; (1.58–60.0) |
| Creatinine, mg/dl, median; (min-max) | 0.92; (0.37–10.57) |
| GFR acc. MDRD formula, ml/min, median; (min-max) | 60; (53–150) |
| Hemoglobin, g/dl, median; (min-max) | 10.9; (6.0–17.3) |
| Neutrophils, G/l, median; (min-max) | 3.2; (0.91–10.1) |
| Platelets, G/l, median; (min-max) | 206; (54–552) |
| Calcium, mmol/l, median; (min-max) | 2.39; (1.8–4.77) |
| Monoclonal protein, g/dl, median; (min-max) | 3.59; (0–14.5) |
| Plasma cells, bone marrow, % median; (min-max) | 37; (0–95) |
| Cytogenetics, del 17p, t(4;14) t(14;16) | 21/100 |
a
ISS was evaluated in 204 patients, for one patient data were unavailable.
b
R-ISS was evaluated in 89 patients (43.4%), since cytogenetic assessment is not a standard procedure in all hematological centers in Poland. ISS, International Staging System; R-ISS, revised International Staging System; VTD, bortezomib, thalidomide, dexamethasone.